Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy

Senti Biosciences Holdings

14/05/2026 13:51

May 14 (Reuters) - Senti Biosciences Holdings Inc SNTI.O:

SENTI BIOSCIENCES HOLDINGS ANNOUNCES POSITIVE FDA RMAT MEETING ON REGISTRATIONAL CLINICAL AND CMC STRATEGY FOR SENTI-202 IN RELAPSED/REFRACTORY AML, ALONG WITH IMPORTANT EFFICACY AND DURABILITY UPDATES ON THE SENTI-202 CLINICAL PROGRAM

SENTI BIOSCIENCES HOLDINGS INC - TO INITIATE SINGLE-ARM MULTI-CENTER REGISTRATION TRIAL FOR SENTI-202 IN R/R AML

SENTI BIOSCIENCES HOLDINGS INC - SENTI-202 FUTURE MANUFACTURING TO USE DONOR X PHENOTYPE

Source text: ID:nGNX36HSqF

Further company coverage: SNTI.O

 ((Reuters.Briefs@thomsonreuters.com;))